By Naomi Kresge; December 21, 2020, 6:03 PM EST
- Companies have projected 1.3 billion doses by end of 2021
- BioNTech will test vaccine for response to strain seen in UK
Pfizer Inc. partner BioNTech SE is pursuing all its options to make more Covid-19 vaccine doses than the 1.3 billion the companies have promised to produce next year, according to the German company’s chief executive officer.
The companies will probably know by January or February whether and how many additional doses can be produced, Ugur Sahin said Monday. “I am confident that we will be able to increase our network capacity, but we don’t have numbers yet,” he said in an interview.
Efficacy results of more than 90% and approvals around the world have set off a race between countries for additional supplies of the precious shots, with the U.S. seeking to exercise an option for a hundred million. Most of the doses anticipated for next year — enough to immunize 650 million people — have already been spoken for.
More than 2 million people in six countries have already gotten their first shot of the standard two-dose regimen, according to data collected by Bloomberg.